DxS Developing KRAS Companion Dx for Bristol-Myers Squibb/ImClone's Erbitux
September 02, 2009
DxS Developing KRAS Companion Dx for Bristol-Myers Squibb/ImClone's Erbitux
"If approved by the FDA, the DxS TheraScreen: K-RAS Mutation Kit would become a companion diagnostic for use with Erbitux in metastatic colorectal cancer to determine which patients have wild-type KRAS status in the US," DxS said this week.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Conference Discussion Questions Big Pharma's True Motivations for Pursuing Personalized Medicine
December 2, 2009 / Pharmacogenomics Reporter - Qiagen Enters Companion Dx Market with Approval of KRAS Test Kit for Erbitux; LDT Impact Unknown
July 11, 2012 / Pharmacogenomics Reporter - Genomic Health Updates Analysts on Companion Dx Pipeline, New Education Campaign
November 10, 2010 / Pharmacogenomics Reporter - PMC Asks FDA to Issue New Guidance Reflecting Rapidly Evolving Rx/Dx Co-development Landscape
December 16, 2009 / Pharmacogenomics Reporter - FDA Adds KRAS Testing Info to Vectibix, Erbitux Labels
July 20, 2009 / GenomeWeb Daily News